Neuroxt
From biomarker-based diagnosis to the appropriate diagnosis of the cure.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | KRW2.2b | Seed | |
| Total Funding | 000k | ||
NeuroXT, founded in 2022 and based in Seoul, South Korea, operates in the HealthTech sector, specializing in AI-powered software for brain disease treatment. The company is led by CEO Sung Joon-kyung, who holds a PhD. NeuroXT develops precision diagnosis software that utilizes MRI data to predict molecular pathology values and determine the suitability of specific therapeutic drugs for patients with degenerative brain diseases.
The firm's core business revolves around creating software solutions that perform biomarker-based diagnostics and assess therapeutic appropriateness using only MRI scans. This is particularly aimed at healthcare centers that may not have access to PET scan protocols. The technology analyzes MRI images to understand the interaction between beta-amyloid and tau proteins, which are key indicators in Alzheimer's disease, with the goal of tailoring treatment plans to individual patients. By doing so, NeuroXT aims to identify the optimal therapeutic window for implementing Alzheimer's drugs, thereby improving patient outcomes and minimizing side effects.
The company's product line includes NEXT-ATN, NEXT-ALZ-CDx, and NEXT-S. NEXT-ATN is an MRI-based algorithm for predicting Amyloid/Tau burden. NEXT-ALZ-CDx is also part of its diagnostic suite. NEXT-S is designed to verify the efficacy of therapeutic drugs targeting synapses by quantifying synaptic durability, an aspect previously unobservable in vivo.
While initially listed as unfunded, records show NeuroXT has participated in accelerator/incubator programs and secured Seed and Early Stage VC funding rounds. Its investors include notable firms such as LG, Samsung Venture Investment, Kakao Ventures, SmileGate Investment, and Korea Investment Accelerator.
Keywords: HealthTech, AI diagnostics, brain disease treatment, medical imaging software, MRI analysis, Alzheimer's disease, precision medicine, biomarker diagnostics, neurodegenerative disease, therapeutic suitability, Sung Joon-kyung, NEXT-ATN, NEXT-ALZ-CDx, NEXT-S, medical software, South Korean startup, digital health, neuro-diagnostics, AI in healthcare, personalized treatment